Biomarkers in the diagnostic algorithm of myalgic encephalomyelitis/chronic fatigue syndrome.
Gravelsina, Sabine, Vilmane, Anda, Svirskis, Simons et al. · Frontiers in immunology · 2022 · DOI
Quick Summary
This study looked for biological markers (measurable signs in the blood) that could help doctors diagnose ME/CFS more easily. Researchers tested 134 ME/CFS patients and 33 healthy people for a virus called HHV-6 and specific antibodies that attack nerve receptors. They found that ME/CFS patients had higher levels of certain antibodies compared to healthy controls, and patients with more virus in their blood tended to have more severe symptoms.
Why It Matters
ME/CFS currently lacks objective diagnostic tests; this study identifies potential blood-based biomarkers that could eventually help clinicians confirm diagnosis more reliably. The findings suggest HHV-6 viral load may be a severity indicator, potentially opening new avenues for understanding disease progression and stratifying patients for treatment.
Observed Findings
HHV-6A/B detection was present in 61% of severe ME/CFS cases (19/31) versus 23% of mild cases (7/30), with severity differences noted at viral loads >1,000 copies/10⁶ PBMCs.
Anti-β2-adrenergic receptor antibodies were significantly elevated in all ME/CFS patient groups (median 1.4 ng/mL) compared to healthy controls (0.81 ng/mL, p=0.0103).
Anti-M4 acetylcholine receptor antibodies were significantly elevated in ME/CFS patients (8.15 ng/mL) versus controls (6.45 ng/mL, p=0.0250).
Increased HHV-6 viral load correlated with increased anti-M4 antibody levels, which in turn correlated with increased anti-β2AdR levels.
Inferred Conclusions
High HHV-6 viral load associates with more severe ME/CFS disease course.
Elevated antibodies against β2-adrenergic and M4 muscarinic acetylcholine receptors are present in ME/CFS patients regardless of clinical severity and may serve as general disease markers.
The relationship between viral load, autoantibodies, and disease severity suggests a possible viral-immune pathogenic pathway in ME/CFS.
Remaining Questions
Are these elevated antibodies functionally pathogenic, or are they merely markers of immune activation induced by viral infection?
Do these biomarker levels change over time in individual patients, and do they fluctuate with symptom severity changes?
What This Study Does Not Prove
This study does not prove that these biomarkers cause ME/CFS or that they are sufficient alone for diagnosis—they were only compared between patient and control groups at a single timepoint. The cross-sectional design cannot establish whether high viral loads precede symptom severity or vice versa, nor whether these biomarkers change over time within individual patients. The study does not demonstrate clinical utility for these markers in routine diagnostic practice.